Recurrent Iron Deficiency Anemia in a Patient with Hb D-Punjab Trait Receiving Tirzepatide
Abstract
Background: Hemoglobin D-Punjab (Hb D-Punjab, also known as Hb D-Los Angeles) is an uncommon structural β-globin variant that is typically clinically silent in the heterozygous state and is not associated with iron deficiency. Recurrent iron deficiency anemia (IDA) despite appropriate oral and intravenous iron replacement warrants a comprehensive evaluation for chronic blood loss, malabsorption, nutritional deficiency, and coexisting hematologic disorders. With the increasing use of incretin-based therapies such as tirzepatide for obesity management, reduced dietary intake has emerged as a potential contributor to micronutrient deficiencies in susceptible individuals. Case Presentation: A 47-year-old woman presented with persistent microcytic hypochromic anemia and recurrent depletion of iron stores despite repeated courses of oral and intravenous iron therapy. Serial laboratory investigations demonstrated hemoglobin values ranging from 11.78 to 13.2 g/dL, with persistent microcytosis (MCV 72.7–77.1 fL), relatively elevated red blood cell counts (4.82–5.42 ×10¹²/L), and recurrently low ferritin levels (as low as 3.1 ng/mL). Hemoglobin electrophoresis demonstrated heterozygous Hb D-Punjab trait (Hb D 40.4%), while persistent microcytosis with a relatively elevated red blood cell count suggested possible coexisting α-thalassemia trait. Evaluation excluded celiac disease, thyroid dysfunction, vitamin B12 deficiency, and gynecological pathology. The patient denied gastrointestinal symptoms but had not undergone endoscopic gastrointestinal evaluation. She had been receiving tirzepatide for weight management, raising the possibility that prolonged appetite suppression and reduced dietary iron intake may have contributed to recurrent iron deficiency, although a causal relationship cannot be established. Conclusion: This case highlights the importance of confirming true biochemical iron deficiency rather than attributing anemia to an incidental hemoglobin variant. Recurrent IDA despite adequate iron replacement requires systematic evaluation for gastrointestinal blood loss, nutritional deficiency, malabsorption, gynecological disorders, and coexisting hematologic conditions. As incretin-based therapies become increasingly used for obesity management, clinicians should remain aware of the potential for nutritional deficiencies in susceptible patients and ensure appropriate clinical and nutritional follow-up.
Keywords: Hemoglobin D-Punjab; Iron deficiency anemia; Tirzepatide; Obesity; Hemoglobinopathy; Microcytic anemia; α-thalassemia trait
Keywords:
Hemoglobin D-Punjab, Iron deficiency anemia, Tirzepatide, Obesity, Hemoglobinopathy, Microcytic anemia, α-thalassemia traitDOI
https://doi.org/10.22270/jddt.v16i10.8049References
1. Camaschella C. Iron deficiency anemia. N Engl J Med. 2015;372(19):1832-1843. https://doi.org/10.1056/NEJMra1401038 PMid:25946282
2. Short MW, Domagalski JE. Iron deficiency anemia: evaluation and management. Am Fam Physician. 2013;87(2):98-104.
3. Bunn HF, Forget BG. Hemoglobin: Molecular, Genetic and Clinical Aspects. Philadelphia: Saunders; 1986.
4. Rahbar S, Rahbar MH. Hemoglobin D-Punjab: a review. Hemoglobin. 2016;40(4):197-202.
5. Galanello R, Origa R. Beta-thalassemia. Orphanet J Rare Dis. 2010;5:11. https://doi.org/10.1186/1750-1172-5-11 PMid:20492708 PMCid:PMC2893117
6. Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide once weekly for the treatment of obesity. N Engl J Med. 2022;387(3):205-216. https://doi.org/10.1056/NEJMoa2206038 PMid:35658024
7. Frias JP, Nauck MA, Van J, et al. Efficacy and safety of tirzepatide versus semaglutide once weekly in type 2 diabetes. Lancet. 2021;398(10295):583-598. https://doi.org/10.1016/S0140-6736(21)01443-4 PMid:34370970
8. Nauck MA, Meier JJ. Incretin hormones: their role in health and disease. Diabetes Obes Metab. 2018;20(S1):5-21. https://doi.org/10.1111/dom.13129 PMid:29364588
9. Mechanick JI, Hurley DL, Garvey WT. Adiposity-based chronic disease as a new diagnostic term: clinical implications. Curr Opin Endocrinol Diabetes Obes. 2017;24(3):151-159.
10. Weatherall DJ, Clegg JB. The Thalassemia Syndromes. 4th ed. Oxford: Blackwell Science; 2001. https://doi.org/10.1002/9780470696705
11. Tolkien Z, Stecher L, Mander AP, et al. Ferrous sulfate supplementation causes significant gastrointestinal side effects. PLoS One. 2015;10(2):e0117383. https://doi.org/10.1371/journal.pone.0117383 PMid:25700159 PMCid:PMC4336293
12. Killip S, Bennett JM, Chambers MD. Iron deficiency anemia. Am Fam Physician. 2007;75(5):671-678.
13. Hutchinson C. Proton pump inhibitors and iron deficiency: a review. Gastroenterol Hepatol Bed Bench. 2013;6(1):1-6.
14. Munro MG, Critchley HO, Fraser IS. FIGO classification of abnormal uterine bleeding. Int J Gynaecol Obstet. 2011;113(1):3-13. https://doi.org/10.1016/j.ijgo.2010.11.011 PMid:21345435
15. Rockey DC. Occult gastrointestinal bleeding. N Engl J Med. 1999;341(1):38-46. https://doi.org/10.1056/NEJM199907013410107 PMid:10387941
16. Weiss G, Goodnough LT. Anemia of chronic disease. N Engl J Med. 2005;352(10):1011-1023. https://doi.org/10.1056/NEJMra041809 PMid:15758012
17. Guyatt GH, Oxman AD, Ali M, et al. Laboratory diagnosis of iron deficiency anemia. J Gen Intern Med. 1992;7(2):145-153. https://doi.org/10.1007/BF02598003 PMid:1487761
18. O’Leary F, Samman S. Vitamin B12 in health and disease. Nutrients. 2010;2(3):299-316. https://doi.org/10.3390/nu2030299 PMid:22254022 PMCid:PMC3257642
19. Rubio-Tapia A, Hill ID, Kelly CP, et al. ACG clinical guidelines: diagnosis and management of celiac disease. Am J Gastroenterol. 2013;108(5):656-676. https://doi.org/10.1038/ajg.2013.79 PMid:23609613 PMCid:PMC3706994
20. Huisman THJ, Carver MFH, Efremov GD. A Syllabus of Human Hemoglobin Variants. Augusta: Medical College of Georgia; 1996.
21. Harteveld CL, Higgs DR. Alpha-thalassemia. Orphanet J Rare Dis. 2010;5:13. https://doi.org/10.1186/1750-1172-5-13 PMid:20507641 PMCid:PMC2887799
22. Steinberg MH. Hemoglobin D and related disorders. In: Disorders of Hemoglobin. Cambridge University Press; 2009.
23. Hoffbrand AV, Moss PAH. Essential Haematology. 7th ed. Wiley-Blackwell; 2016.
24. Bain BJ. Haemoglobinopathy Diagnosis. 2nd ed. Wiley-Blackwell; 2011.
25. Goddard AF, James MW, McIntyre AS, et al. Guidelines for the management of iron deficiency anemia. Gut. 2011;60(10):1309-1316. https://doi.org/10.1136/gut.2010.228874 PMid:21561874
26. Rockey DC, Cello JP. Evaluation of gastrointestinal tract in iron deficiency anemia. N Engl J Med. 1993;329(23):1691-1695. https://doi.org/10.1056/NEJM199312023292303 PMid:8179652
27. DeLoughery TG. Microcytic anemia. N Engl J Med. 2014;371(14):1324-1331. https://doi.org/10.1056/NEJMra1215361 PMid:25271605
28. Auerbach M, Adamson JW. How we diagnose and treat iron deficiency anemia. Am J Hematol. 2016;91(1):31-38. https://doi.org/10.1002/ajh.24201 PMid:26408108
29. Mechanick JI, Youdim A, Jones DB, et al. Clinical practice guidelines for obesity. Endocr Pract. 2013;19(2):337-372. https://doi.org/10.4158/EP12437.GL PMid:23529351
30. Lupsa BC, Inzucchi SE. Incretin-based therapies and micronutrient deficiencies. Curr Diab Rep. 2013;13(4):514-521.
31. Jastreboff AM, Kotz CM, Kahan S. Obesity pharmacotherapy and nutritional considerations. Obesity (Silver Spring). 2023;31(1):12-22.
Published
Abstract Display: 0
PDF Downloads: 0
PDF Downloads: 0 How to Cite
Issue
Section
Copyright (c) 2026 Maryam Hassan Mohammed El Akkam , Rania Murad , Ashraf Alakkad

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0). that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).

.